Peripheral cholesterol, metabolic disorders and Alzheimer's disease

Frontiers in Bioscience - Elite

Volumn 4 E, Issue 1, 2012, Pages 181-194

  Ledesma, Maria Dolores ^a   Dotti, Carlos Gerardo ^a,b,c  

^a CENTRO DE BIOLOGÍA MOLECULAR SEVERO OCHOA   (Spain)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Alzheimer's Disease; Atherosclerosis; Brain Blood Barrier; Diabetes; Hypercholesterolemia; Insulin; Leptin; Obesity; Review

Indexed keywords

2 AZETIDINONE DERIVATIVE; ABC TRANSPORTER A1; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; THIAZOLIDINE DERIVATIVE;

ALZHEIMER DISEASE; ARTICLE; ATHEROSCLEROSIS; CAUSE OF DEATH; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; DIABETES MELLITUS; HUMAN; HYPERCHOLESTEROLEMIA; INSULIN RELEASE; INSULIN RESISTANCE; METABOLIC DISORDER; OBESITY; RISK FACTOR; METABOLISM; REVIEW;

ALZHEIMER DISEASE; CHOLESTEROL; DIABETES MELLITUS; HUMANS; METABOLIC DISEASES; OBESITY;

EID: 84858993066     PISSN: 19450494     EISSN: 19450508     Source Type: Journal    
DOI: 10.2741/e368     Document Type: Article

References (151)

1. D.H. Small, S.S. Mok and J.C. Bornstein: Alzheimer's disease and Abeta toxicity: from top to bottom. Nat. Rev. Neurosci. 2, 595-598 (2001)
2. D.L. Price and S.S. Sisodia: Mutant genes in familial Alzheimer's disease and transgenic models. Annu. Rev. Neurosci. 21, 479-505 (1998)
3. K. Fassbender, M. Simons, C. Bergmann, M. Stroick, D. Lutjohann, P. Keller, H. Runz, S. Kuhl, T. Bertsch, K. von Bergmann, M. Hennerici, K. Beyreuther and T. Hartmann: Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc. Natl. Acad.Sci. U. S. A. 98, 5856-5861 (2001)
4. J. Abad-Rodriguez, M.D. Ledesma, K. Craessaerts, S. Perga, M.Medina, A. Delacourte, C. Dingwall, B. De Strooper and C.G. Dotti: Neuronal membrane cholesterol loss enhances amyloid peptide generation. J. Cell Biol. 167, 953-960 (2004)
5. B. Hutter-Paier, H.J.Huttunen, L.Puglielli, C.B.Eckman, D.Y.Kim, A. Hofmeister,R.D. Moir, S.B. Domnitz, M.P. Frosch, M. Windisch and D.M. Kovacs: The ACAT inhibitor CP-113,818 markedly reduces amyloid pathology in a mouse model of Alzheimer's disease. Neuron 44, 227-238 (2004)
6. A. Crameri, E. Biondi, K. Kuehnle, D. Lutjohann, K.M. Thelen, S. Perga, C.G. Dotti, R.M. Nitsch, M.D. Ledesma and M.H. Mohajeri: The role of seladin-1/DHCR24 in colesterol biosynthesis, APP processing and Abeta generation in vivo, EMBO J. 25, 432-443 (2006)
7. A.M. Nicholson and A. Ferreira: Increased membrane cholesterol might render mature hippocampal neurons more susceptible to beta-amyloid-induced calpain activation and tau toxicity. J Neurosci. 29, 4640-4651 (2009)
8. M.D. Ledesma and C.G. Dotti CG: Amyloid excess in Alzheimer's disease: what is cholesterol to be blamed for? FEBS Lett. 580, 5525-5532 (2006)
9. L. Canevari and J.B. Clark: Alzheimer's disease and cholesterol: the fat connection. Neurochem Res. 32, 739-750 (2007)
10. R.Bhattacharyya and D.M. Kovacs: ACAT inhibition and amyloid beta reduction. Biochim Biophys Acta.1801, 960-965 (2010)
11. J.M. Dietschy and S.D. Turley: Cholesterol metabolism in the brain, Curr. Opin. Lipidol. 12, 105-112 (2001)
12. H. Jick, G.L. Zornberg, S.S. Jick, S. Seshadri and D.A. Drachman: Statins and the risk of dementia, Lancet 356, 1627-1631 (2000)
13. B. Wolozin, W. Kellman, P. Ruosseau, G.G. Celesia and G. Siegel: Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3- methyglutaryl coenzyme A reductase inhibitors, Arch. Neurol. 57, 1439-1443 (2000)
14. J.L. Goldstein and M.S. Brown: Regulation of the mevalonate pathway, Nature 343, 425-430 (1990)
15. K.J. Anstey, D.M. Lipnicki and L.F. Low: Cholesterol as a risk factor for dementia and cognitive decline: a systematic review of prospective studies with metaanalysis. Am J Geriatr Psychiatry. 16, 343-354 (2008)
16. E.H. Corder, A.M. Saunders, W.J. Strittmatter, D.E. Schmechel, P.C. Gaskell, G.W. Small, A.D. Roses, J.L. Haines and M.A. Pericak-Vance: Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261, 921-923 (1993)
17. A. Merched, Y. Xia, S. Visvikis, J.M. Serot and G. Siest: Decreased high-density lipoprotein cholesterol and serum apolipoprotein AI concentrations are highly correlated with the severity of Alzheimer's disease. Neurobiol Aging. 21, 27-30 (2000)
18. J. Davignon, R.E. Gregg and S.F. Sing: Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis.8, 1-21 (1988)
19. L. Braeckman, D. De Bacquer, M. Rosseneu and G. De Backer: Apolipoprotein E polymorphism in middle-aged Belgian men: phenotype distribution and relation to serum lipids and lipoproteins. Atherosclerosis. 120, 67-73 (1996)
20. R. Frikke-Schmidt, B.G. Nordestgaard, B. Agerholm-Larsen, P. Schnohr and A. Tybjaerg-Hansen: Context-dependent and invariant associations between lipids, lipoproteins, and apolipoproteins and apolipoprotein E genotype. J Lipid Res. 41, 1812-1822 (2000)
21. T. Hoshino, K. Kamino and M. Matsumoto: Gene dose effect of the APOE-epsilon4 allele on plasma HDL cholesterol level in patients with Alzheimer's disease. Neurobiol Aging. 23, 41-45 (2002)
22. M. Michikawa, Q.W. Fan, I. Isobe, K. Yanagisawa: Apolipoprotein E exhibits isoform-specific promotion of lipid efflux from astrocytes and neurons in culture. J Neurochem. 74, 1008-1016 (2000)
23. J.S. Gong, M. Kobayashi, H. Hayashi, K. Zou, N. Sawamura, S.C. Fujita, K. Yanagisawa and M. Michikawa: Apolipoprotein E (ApoE) isoform-dependent lipid release from astrocytes prepared from human ApoE3 and ApoE4 knock-in mice. J Biol Chem. 277, 29919-29926 (2002)
24. A.M. Fagan, L.H. Younkin, J.C. Morris, J.D. Fryer, T.G. Cole, S.G. Younkin and D.M. Holtzman: Differences in the Abeta40/Abeta42 ratio associated with cerebrospinal fluid lipoproteins as a function of apolipoprotein E genotype. Ann Neurol. 48, 201-210 (2000)
25. K. Fassbender, M. Stroick, T. Bertsch, A. Ragoschke, S. Kuehl, S. Walter, J. Walter, K. Brechtel, F. Muehlhauser, K. Von Bergmann and D. Lütjohann: Effects of statins on human cerebral cholesterol metabolism and secretion of Alzheimer amyloid peptide. Neurology. 59, 1257-1258 (2002)
26. R.P. Kloppenborg, E. van den Berg, L.J. Kappelle and G.J. Biessels: Diabetes and other vascular risk factors for dementia: which factor matters most? A systematic review. Eur J Pharmacol. 585, 97-108 (2008)
27. A. Jones, P. Kulozik, A. Ostertag and S. Herzig: Common pathological processes and transcriptional pathways in Alzheimer's disease and type 2 diabetes. J Alzheimers Dis. 16, 787-808 (2009)
28. J. Janson, T. Laedtke, J.E. Parisi, P. ÓBrien, R.C. Petersen and P.C. Butler: Increased risk of type 2 diabetes in Alzheimer disease. Diabetes. 53, 474-481 (2004)
29. J.K. Kruit, L.R. Brunham, C.B. Verchere and M.R. Hayden: HDL and LDL cholesterol significantly influence beta-cell function in type 2 diabetes mellitus. Curr Opin Lipidol. 21, 178-185 (2010)
30. A. von Eckardstein and G. Assmann. Prevention of coronary heart disease by raising high-density lipoprotein cholesterol? Curr Opin Lipidol. 11, 627-637 (2000)
31. L.R. Brunham, J.J. Kastelein and M.R. Hayden: ABCA1 gene mutations, HDL cholesterol levels, and risk of ischemic heart disease. JAMA. 300, 1997-1998 (2008)
32. M. Vergeer, L.R. Brunham, J. Koetsveld, J.K. Kruit, C.B.Verchere, J.J. Kastelein, M.R. Hayden and E.S. Stroes: Carriers of loss-of-function mutations in ABCA1 display pancreatic beta-cell dysfunction. Diabetes Care. 33, 869-74 (2010)
33. R.R. Singaraja, L.R. Brunham, H. Visscher, J.J. Kastelein and M.R. Hayden: Efflux and atherosclerosis: the clinical and biochemical impact of variations in the ABCA1 gene. Arterioscler Thromb Vasc Biol. 23, 1322-1332 (2003)
34. L.R. Brunham, J.K. Kruit, T.D. Pape, J.M. Timmins, A.Q. Reuwer, Z. Vasanji, B.J. Marsh, B. Rodrigues, J.D. Johnson, J.S. Parks, C.B. Verchere and M.R. Hayden: Betacell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. Nat Med. 13, 340-347 (2007)
35. L.R. Brunham, J.K. Kruit, M.R. Hayden and C.B. Verchere: Cholesterol in beta-cell dysfunction: the emerging connection between HDL cholesterol and type 2 diabetes. Curr Diab Rep. 10, 55-60 (2010)
36. M.S. Brown and J.L. Goldstein: The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell. 89, 331-340 (1997)
37. M. Ishikawa, Y. Iwasaki, S. Yatoh, T. Kato, S. Kumadaki, N. Inoue, T. Yamamoto, T. Matsuzaka, Y. Nakagawa, N. Yahagi, K. Kobayashi, A. Takahashi, N. Yamada and H. Shimano: Cholesterol accumulation and diabetes in pancreatic beta-cell-specific SREBP-2 transgenic mice: a new model for lipotoxicity. J Lipid Res. 49, 2524-2534 (2008)
38. E. Rodriguez-Rodriguez, I. Mateo, J. Llorca, C. Sánhez-Quintana, J. Infante, I. García-Gorostiaga, P. Sánchez-Juan, J. Berciano and O. Combarros: Association of genetic variants of ABCA1 with Alzheimer's disease risk. Am J Med Genet B Neuropsychiatr Genet. 144B, 964-968 (2007)
39. C.A. Reynolds, M.G. Hong, U.K. Eriksson, K. Blennow, A.M. Bennet, JB. B. Johansson, B. Malmberg, S. Berg, F. Wiklund, M. Gatz, N.L. Pedersen and J.A. Prince: A survey of ABCA1 sequence variation confirms association with dementia. Hum Mutat. 1348-1354 (2009)
40. C.A. Reynolds, M.G. Hong, U.K. Eriksson, K. Blennow, F. Wiklund, B. Johansson, B. Malmberg, S. Berg, A. Alexeyenko, H. Grönberg, M. Gatz, N.L. Pedersen, J.A. Prince: Analysis of lipid pathway genes indicates association of sequence variation near SREBF1/TOM1L2/ATPAF2 with dementia risk. Hum Mol Genet. 19, 2068-2078 (2010)
41. S. Le Hellard, T.W.Mühleisen, S. Djurovic, J. Fernø, Z. Ouriaghi, M. Mattheisen, C. Vasilescu, M.B. Raeder, T. Hansen, J. Strohmaier, A. Georgi, F.F. Brockschmidt, I. Melle, I. Nenadic, H. Sauer, M. Rietschel, M.M. Nöthen, T. Werge, O.A. Andreassen, S. Cichon and V.M. Steen: Polymorphisms in SREBF1 and SREBF2, two antipsychotic-activated transcription factors controlling cellular lipogenesis, are associated with schizophrenia in German and Scandinavian samples. Mol Psychiatry. 15, 463-72 (2010)
42. G.J. Biessels, E.J. Stevens, S.J. Mahmood, W.H. Gispen, D.R. Tomlinson: Insulin partially reverses deficits in peripheral nerve blood flow and conduction in experimental diabetes. J Neurol Sci. 140, 12-20 (1996)
43. G.J. Biessels, A. Kamal, I.J. Urban, B.M. Spruijt, D.W. Erkelens and W.H. Gispen Water maze learning and hippocampal synaptic plasticity in streptozotocin-diabetic rats: effects of insulin treatment. Brain Res. 800, 125-35 (1998)
44. W. Kern, A. Peters, B. Fruehwald-Schultes, E. Deininger, J. Born, H.L. Fehm: Improving influence of insulin on cognitive functions in humans. Neuroendocrinology. 74, 270-280 (2001)
45. M. Mulder, A. Blokland, D.J. van den Berg, H. Schulten, A.H. Bakker, D. Terwel, W. Honig, E.R. de Kloet, L.M. Havekes, H.W. Steinbusch and E.C. de Lange: Apolipoprotein E protects against neuropathology induced by a high-fat diet and maintains the integrity of the blood-brain barrier during aging. Lab Invest. 81, 953-960 (2001)
46. R. Kalayci, M. Kaya, H. Uzun, B. Bilgic, B. Ahishali, N. Arican, I. Elmas, M. Küçük: Influence of hypercholesterolemia and hypertension on the integrity of the blood-brain barrier in rats. Int J Neurosci. 119, 1881-904 (2009)
47. R. Deane and B.V. Zlokovic: Role of the blood-brain barrier in the pathogenesis of Alzheimer's disease. Curr Alzheimer Res. 4, 191-197 (2007)
48. K.F. Neumann, L. Rojo, L.P. Navarrete, G. Farías, P. Reyes and R.B. Maccioni: Insulin resistance and Alzheimer's disease: molecular links & clinical implications. Curr Alzheimer Res. 5, 438-447 (2008)
49. S. Craft, E. Peskind, M.W. Schwartz, G.D. Schellenberg, M. Raskind and D Jr. Porte: Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology. 50, 164-168 (1998)
50. E. Planel, Y. Tatebayashi, T. Miyasaka, L. Liu, L. Wang, M. Herman, W.H. Yu, J.A. Luchsinger, B. Wadzinski, K.E. Duff and A. Takashima: Insulin dysfunction induces in vivo tau hyperphosphorylation through distinct mechanisms. J Neurosci. 27, 13635-13648 (2007)
51. Y.D. Ke, F. Delerue, A. Gladbach, J. Götz and L.M. Ittner: Experimental diabetes mellitus exacerbates tau pathology in a transgenic mouse model of Alzheimer's disease. PLoS One. 4:e7917 (2009)
52. Y.W. Liu, L. Liu, S.S. Lu, D.L. Wang, X.D. Liu, L. Xie and G.J. Wang: Impaired amyloid beta-degrading enzymes in brain of streptozotocin-induced diabetic rats. J Endocrinol Invest. 2010 Apr 22. [Epub ahead of print]
53. E. Carro and I. Torres-Aleman: The role of insulin and insulin-like growth factor I in the molecular and cellular mechanisms underlying the pathology of Alzheimer's disease. Eur J Pharmacol. 490, 127-133 (2004)
54. L. Gasparini, G.K. Gouras, R. Wang, R.S. Gross, M.F. Beal, P. Greengard and H. Xu: Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling. J Neurosci. 21, 2561-2570 (2001)
55. G.S. Watson, E.R. Peskind, S. Asthana, K. Purganan, C. Wait, D. Chapman, M.W. Schwartz, S. Plymate and S. Craft: Insulin increases CSF Abeta42 levels in normal older adults. Neurology. 60, 1899-1903 (2003)
56. M. Kivipelto, T. Ngandu, L. Fratiglioni, M. Viitanen, I. Kåreholt, B. Winblad, E.L. Helkala, J. Tuomilehto, H. Soininen and A. Nissinen: Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch Neurol. 62, 1556-1560 (2005)
57. R.A. Whitmer: The epidemiology of adiposity and dementia. Curr Alzheimer Res. 4, 117-122 (2007)
58. J.A. Luchsinger and D.R. Gustafson: Adiposity and Alzheimer's disease. Curr Opin Clin Nutr Metab Care. 12, 15-21 (2009)
59. K. Balakrishnan, G. Verdile, P.D. Mehta, J. Beilby, D. Nolan, D.A. Galvão, R. Newton, S.E. Gandy and R.N. Martins: Plasma Abeta42 correlates positively with increased body fat in healthy individuals. J Alzheimers Dis. 8, 269-282 (2005)
60. E.A. Sims, E Jr Danforth, E.S. Horton, G.A. Bray, J.A. Glennon and L.B. Salans: Endocrine and metabolic effects of experimental obesity in man. Recent Prog Horm Res. 29, 457-96 (1973)
61. F.X. Pi-Sunyer: Medical hazards of obesity. Ann Intern Med. 119, 655-60 (1993)
62. E. Ferrannini: Insulin resistance is central to the burden of diabetes. Diabetes Metab Rev. 13, 81-86 (1997)
63. J.A. Luchsinger: Adiposity, hyperinsulinemia, diabetes and Alzheimer's disease: an epidemiological perspective. Eur J Pharmacol. 585, 119-129 (2008)
64. T.B. Van Itallie: Health implications of overweight and obesity in the United States. Ann Intern Med. 103, 983-988 (1985)
65. P. Karhapää, M. Malkki and M. Laakso: Isolated low HDL cholesterol. An insulin-resistant state. Diabetes. 43, 411-417 (1994)
66. S.M. Grundy and G.L. Vega: Causes of high blood cholesterol. Circulation. 81, 412-427 (1990)
67. M.A. Austin and K.L. Edwards: Small, dense low density lipoproteins, the insulin resistance syndrome and noninsulin-dependent diabetes. Curr Opin Lipidol. 7, 167-171 (1996)
68. R.M. Krauss: Triglycerides and atherogenic lipoproteins: rationale for lipid management. Am J Med. 105, 58S-62S (1998)
69. K.J. Kaiyala, R.L. Prigeon, S.E. Kahn, S.C. Woods and M.W. Schwartz: Obesity induced by a high-fat diet is associated with reduced brain insulin transport in dogs. Diabetes. 49, 1525-1533 (2000)
70. M.W. Schwartz, S.C. Woods, D Jr. Porte, R.J. Seeley and D.G. Baskin: Central nervous system control of food intake. Nature. 404, 661-671 (2000)
71. S.P. Kalra: Central leptin gene therapy ameliorates diabetes type 1 and 2 through two independent hypothalamic relays; a benefit beyond weight and appetite regulation. Peptides. 30, 1957-1963 (2009)
72. E. Ur, D.A. Wilkinson, B.A. Morash and M. Wilkinson: Leptin immunoreactivity is localized to neurons in rat brain. Neuroendocrinology. 75, 264-272 (2002)
73. L.A. Campfield, F.J. Smith and P. Burn P: The OB protein (leptin) pathway-a link between adipose tissue mass and central neural networks. Horm Metab Res. 28, 619-632 (1996)
74. A.J. Kastin and V. Akerstrom: Glucose and insulin increase the transport of leptin through the blood-brain barrier in normal mice but not in streptozotocin-diabetic mice. Neuroendocrinology. 73, 237-242 (2001)
75. W.A. Banks: The source of cerebral insulin. Eur J Pharmacol. 49, 5-12 (2004)
76. W.A. Banks, C.R. DiPalma and C.L. Farrell: Impaired transport of leptin across the blood-brain barrier in obesity. Peptides. 20, 1341-1345 (1999)
77. L.J. Shanley, A.J. Irving and J. Harvey: Leptin enhances NMDA receptor function and modulates hippocampal synaptic plasticity. J Neurosci. 21, RC186 (2001)
78. P.R. Moult, B. Milojkovic and J. Harvey: Leptin reverses long-term potentiation at hippocampal CA1 synapses. J Neurochem. 108, 685-696 (2009)
79. P.R. Moult and J. Harvey: Regulation of glutamate receptor trafficking by leptin. Biochem Soc Trans. 37, 1364-1368 (2009)
80. N. Tezapsidis, J.M. Johnston, M.A. Smith, J.W. Ashford, G. Casadesus, N.K. Robakis, B. Wolozin, G. Perry, X. Zhu, S.J. Greco and S. Sarkar: Leptin: a novel therapeutic strategy for Alzheimer's disease. J Alzheimers Dis. 16, 731-740 (2009)
81. S.J. Greco, K.J. Bryan, S. Sarkar, X. Zhu, M.A. Smith, J.W. Ashford, J.M. Johnston, N. Tezapsidis and G. Casadesus: Leptin reduces pathology and improves memory in a transgenic mouse model of Alzheimer's disease. J Alzheimers Dis. 19, 1155-1167 (2010)
82. G. Marwarha, B. Dasari, J.R. Prasanthi, J. Schommer and O. Ghribi: Leptin reduces the accumulation of Abeta and phosphorylated tau induced by 27-hydroxycholesterol in rabbit organotypic slices. J Alzheimers Dis. 19, 1007-1019 (2010)
83. K.F. Holden, K. Lindquist, F.A. Tylavsky, C. Rosano, T.B. Harris and K. Yaffe: Serum leptin level and cognition in the elderly: Findings from the Health ABC Study. Neurobiol Aging. 30, 1483-1489 (2009)
84. W. Lieb, A.S. Beiser, R.S. Vasan, Z.S. Tan, R. Au, T.B. Harris, R. Roubenoff, S. Auerbach, C. DeCarli, P.A. Wolf and S. Seshadri: Association of plasma leptin levels with incident Alzheimer disease and MRI measures of brain aging. JAMA. 302, 2565-2572 (2009)
85. A.B. Newman, A.L. Fitzpatrick, O. Lopez, S. Jackson, C. Lyketsos, W. Jagust, D. Ives, S.T. Dekosky, L.H. Kuller: Dementia and Alzheimer's disease incidence in relationship to cardiovascular disease in the Cardiovascular Health Study cohort. J Am Geriatr Soc. 53, 1101-1107 (2005)
86. L.S. Honig, W. Kukull and R. Mayeux: Atherosclerosis and AD: analysis of data from the US National Alzheimer's Coordinating Center. Neurology. 64, 494-500 (2005)
87. C.M. Hulette and K. Welsh-Bohmer: Coronary artery disease is associated with Alzheimer disease neuropathology in APOE4 carriers. Neurology. 68, 471 (2007)
88. L. Li, D. Cao, D.W. Garber, H. Kim and K. Fukuchi: Association of aortic atherosclerosis with cerebral beta-amyloidosis and learning deficits in a mouse model of Alzheimer's disease. Am J Pathol. 163, 2155-2164 (2003)
89. H. Imrie, A. Abbas and M. Kearney: Insulin resistance, lipotoxicity and endothelial dysfunction. Biochim Biophys Acta. 1801, 320-326 (2010)
90. G.H. Tomkin: Atherosclerosis, diabetes and lipoproteins. Expert Rev Cardiovasc Ther. 8, 1015-1029 (2010)
91. G. Poli, B. Sottero, S. Gargiulo and G. Leonarduzzi: Cholesterol oxidation products in the vascular remodeling due to atherosclerosis. Mol Aspects Med. 30, 180-189 (2009)
92. K. Alwaili, Z. Awan, A. Alshahrani and J. Genest: High-density lipoproteins and cardiovascular disease: 2010 update. Expert Rev Cardiovasc Ther. 8, 413-423 (2010)
93. X. Prieur, T. Roszer and M. Ricote: Lipotoxicity in macrophages: evidence from diseases associated with the metabolic syndrome. Biochim Biophys Acta. 1801, 327-337 (2010)
94. I. Tabas: Cholesterol in health and disease. J Clin Invest. 110, 583-590 (2002)
95. F.R. Maxfield and I. Tabas: Role of cholesterol and lipid organization in disease. Nature. 438, 612-621 (2005)
96. R.R. Singaraja, L.R. Brunham, H. Visscher, J.J. Kastelein and M.R. Hayden: Efflux and atherosclerosis: the clinical and biochemical impact of variations in the ABCA1 gene. Arterioscler Thromb Vasc Biol. 23, 1322-1332 (2003)
97. L. Yvan-Charvet, M. Ranalletta, N. Wang, S. Han, N. Terasaka, R. Li, C. Welch, A.R.Tall: Combined deficiency of ABCA1 and ABCG1 promotes foam cell accumulation and accelerates atherosclerosis in mice. J Clin Invest. 117, 3900-3908 (2007)
98. I. Tabas: Cholesterol and phospholipid metabolism in macrophages. Biochim Biophys Acta. 1529, 164-174 (2000)
99. R.D. Bell and B.V. Zlokovic: Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta Neuropathol. 118, 103-113 (2009)
100. C.G. Dotti and B. De Strooper: Alzheimer's dementia by circulation disorders: when trees hide the forest. Nat Cell Biol. 11, 114-116 (2009)
101. J.C. de la Torre: Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet Neurol. 3, 184-190 (2004)
102. J.C. de la Torre: How do heart disease and stroke become risk factors for Alzheimer's disease? Neurol Res. 28, 637-644 (2006)
103. C. Zhiyou, Y. Yong, S. Shanquan, Z. Jun, H. Liangguo, Y. Ling and L. Jieying: Upregulation of BACE1 and beta-amyloid protein mediated by chronic cerebral hypoperfusion contributes to cognitive impairment and pathogenesis of Alzheimer's disease. Neurochem Res. 34, 1226-1235 (2009)
104. H. Kitaguchi, H. Tomimoto, M. Ihara, M. Shibata, K. Uemura, R.N. Kalaria, T. Kihara, M. Asada-Utsugi, A. Kinoshita and R. Takahashi: Chronic cerebral hypoperfusion accelerates amyloid beta deposition in APPSwInd transgenic mice. Brain Res. 1294, 202-210 (2009)
105. R.S. Rosenson: Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities. Atherosclerosis. 173, 1-12 (2004)
106. D.J. Betteridge: Lipid lowering in diabetes mellitus. Curr Opin Lipidol. 19, 579-584 (2008)
107. J. Ferrières: Effects on coronary atherosclerosis by targeting low-density lipoprotein cholesterol with statins. Am J Cardiovasc Drugs. 9, 109-115 (2009)
108. S. Trompet, P. van Vliet, A.J. de Craen, J. Jolles, B.M. Buckley, M.B. Murphy, I. Ford, P.W. Macfarlane, N. Sattar, C.J. Packard, D.J. Stott, J. Shepherd, E.L. Bollen, G.J. Blauw, J.W. Jukema, R.G. Westendorp:. Pravastatin and cognitive function in the elderly. Results of the PROSPER study. J Neurol. 257, 85-90 (2010)
109. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet, 360, 7-22 (2002)
110. G.A. Cardenas, C.J. Lavie, V. Cardenas, R.V. Milani and P.A. McCullough: The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management. Rev Cardiovasc Med. 9, 239-258 (2008)
111. D.C. Hess, A.M. Demchuk, L.M. Brass and F.M. Yatsu: HMG-CoA reductase inhibitors (statins): a promising approach to stroke prevention. Neurology. 54, 790-796 (2000)
112. P.H. Chong, R. Kezele and C. Franklin: Highdensity lipoprotein cholesterol and the role of statins. Circ J. 66, 1037-1044 (2002)
113. C. Gagné, H.E. Bays, S.R. Weiss, P. Mata, K. Quinto, M. Melino, M. Cho, T.A. Musliner and B. Gumbiner: Ezetimibe Study Group. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol. 90, 1084-1091 (2002)
114. M.A. Al-Mohaissen, S.C. Pun and J.J. Frohlich: Niacin: from mechanisms of action to therapeutic uses. Mini Rev Med Chem. 10, 204-217 (2010)
115. P.J. Barter, H.B. Jr Brewer, M.J. Chapman, C.H. Hennekens, D.J. Rader and A.R. Tall: Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol. 23, 160-167 (2003)
116. M.J. Chapman, W. Le Goff, M. Guerin and A. Kontush: Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. Eur Heart J. 31, 149-164 (2010)
117. P.O. Szapary and D.J. Rader: Pharmacological management of high triglycerides and low high-density lipoprotein cholesterol. Curr Opin Pharmacol. 1, 113-20 (2001)
118. W. Le Goff, M. Guerin and M.J. Chapman: Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia. Pharmacol Ther. 101, 17-38 (2004)
119. M. Hernandez, S.D. Wright and T.Q. Cai: Critical role of cholesterol ester transfer protein in nicotinic acid mediated HDL elevation in mice. Biochem Biophys Res Commun. 355, 1075-1080 (2007)
120. R. Gurfinkel and T.R. Joy: Anacetrapib: Hope for CETP Inhibitors? Cardiovasc Ther. 2010 Apr 9.
121. E. Rodríguez, I. Mateo, J. Infante, J. Llorca, J. Berciano and O. Combarros: Cholesteryl ester transfer protein (CETP) polymorphism modifies the Alzheimer's disease risk associated with APOE epsilon4 allele. J Neurol. 253, 181-185 (2006)
122. D.W. Chen, J.F. Yang, Z. Tang, X.M. Dong, X.L. Feng, S. Yu and P. Chan: Cholesteryl ester transfer protein polymorphism D442G associated with a potential decreased risk for Alzheimer's disease as a modifier for APOE epsilon4 in Chinese. Brain Res. 1187, 52-57 (2008)
123. H.J. Knowles, R.H. te Poele, P. Workman and A.L. Harris: Niacin induces PPARgamma expression and transcriptional activation in macrophages via HM74 and HM74a-mediated induction of prostaglandin synthesis pathways. Biochem Pharmacol. 71, 646-656 (2006)
124. T. Rubic, M. Trottmann and R.L. Lorenz: Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin. Biochem Pharmacol. 67, 411-419 (2004)
125. A. Gille, E.T. Bodor, K. Ahmed and S. Offermanns: Nicotinic acid: pharmacological effects and mechanisms of action. Annu Rev Pharmacol Toxicol. 48, 79-106 (2008)
126. R.S. Blumenthal and E.D. Michos: The HALTS trial-halting atherosclerosis or halted too early? N Engl J Med. 361, 2178-2180 (2009)
127. H. Neeli, R. Gadi and D.J. Rader: Managing diabetic dyslipidemia: beyond statin therapy. Curr Diab Rep. 9, 11-17 (2009)
128. M.C. Morris, D.A. Evans, J.L. Bienias, P.A. Scherr, C.C. Tangney, L.E. Hebert, D.A. Bennett, R.S. Wilson and N. Aggarwal: Dietary niacin and the risk of incident Alzheimer's disease and of cognitive decline. J Neurol Neurosurg Psychiatry. 75, 1093-1099 (2004)
129. S.W. Altmann, H.R. Jr Davis, L.J. Zhu, X. Yao, L.M. Hoos, G. Tetzloff, S.P. Iyer, M. Maguire, A. Golovko, M. Zeng, L. Wang, N. Murgolo and M.P. Graziano. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science. 303, 1201-1204 (2004)
130. H.R. Jr Davis, L.J. Zhu, L.M. Hoos, G. Tetzloff, M. Maguire, J. Liu, X. Yao, S.P. Iyer, M.H. Lam, E.G. Lund, P.A. Detmers, M.P. Graziano and S.W. Altmann: Niemann-Pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis. J Biol Chem. 279, 33586-33592 (2004)
131. M. Garcia-Calvo, J. Lisnock, H.G. Bull, B.E. Hawes, D.A. Burnett, M.P. Braun, J.H. Crona, H.R. Jr Davis, D.C. Dean, P.A. Detmers, M.P. Graziano, M. Hughes, D.E. MacIntyre, A. Ogawa, K.A. Óneill, S.P. Iyer, D.E. Shevell, M.M. Smith, Y.S. Tang, A.M. Makarewicz, F. Ujjainwalla, S.W. Altmann, K.T. Chapman and N.A. Thornberry: The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1) Proc Natl Acad Sci U S A. 102, 8132-8137 (2005)
132. R.E. Temel, W.Tang, Y. Ma, L.L. Rudel, M.C. Willingham, Y.A. Ioannou, J.P. Davies, L.M. Nilsson and L. Yu: Hepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe. J Clin Invest. 117, 1968-1978 (2007)
133. S. Katragadda, F. Rai and R. Arora: Dual inhibition, newer paradigms for cholesterol lowering. Am J Ther. 17, e88-99 (2010)
134. S.E. Wahrle, H. Jiang, M. Parsadanian, J. Kim, A. Li, A. Knoten, S. Jain, V. Hirsch-reinshagen, C.L. Wellington, K.R. Bales, S.M. Paul and D.M. Holtzman: Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J Clin Invest. 118, 671-682 (2008)
135. E. Rodríguez-Rodríguez, I. Mateo, J. Llorca, C. Sánchez-Quintana, J. Infante, I. García-Gorostiaga, P. Sánchez-Juan, J. Berciano and O. Combarros: Association of genetic variants of ABCA1 with Alzheimer's disease risk. Am J Med Genet B Neuropsychiatr Genet. 144B, 964-968 (2007)
136. C. Tang and J.F. Oram: The cell cholesterol exporter ABCA1 as a protector from cardiovascular disease and diabetes. Biochim Biophys Acta. 1791, 563-572 (2009)
137. M. Ogata, M. Tsujita, M.A. Hossain, N. Akita, F.J. Gonzalez, B. Staels, S. Suzuki, T. Fukutomi, G. Kimura and S. Yokoyama: On the mechanism for PPAR agonists to enhance ABCA1 gene expression. Atherosclerosis. 205, 413-419 (2009)
138. S. Jeong, M. Han, H. Lee, M. Kim, J. Kim, C.J. Nicol, B.H. Kim, J.H. Choi, K.H. Nam, G.T. Oh and M. Yoon: Effects of fenofibrate on high-fat diet-induced body weight gain and adiposity in female C57BL/6J mice. Metabolism. 53, 1284-1289 (2004)
139. G. Steiner: The use of fibrates and of statins in preventing atherosclerosis in diabetes. Curr Opin Lipidol. 12, 611-617 (2001)
140. I. Blasko, S. Jungwirth, K. Jellinger, G. Kemmler, W. Krampla, S. Weissgram, I. Wichart, K.H. Tragl, H. Hinterhuber and P. Fischer: Effects of medications on plasma amyloid beta (Abeta) 42: longitudinal data from the VITA cohort. J Psychiatr Res. 42, 946-955 (2008)
141. C. Dufouil, F. Richard, N. Fiévet, J.F. Dartigues, K. Ritchie, C. Tzourio, P. Amouyel and A. Alpérovitch: APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: the Three-City Study. Neurology. 64, 1531-1538 (2005)
142. T. Kukar, M.P. Murphy, J.L. Eriksen, S.A. Sagi, S. Weggen, T.E. Smith, T. Ladd, M.A. Khan, R. Kache, J. Beard, M. Dodson, S. Merit, V.V. Ozols, P.Z. Anastasiadis, P. Das, A. Fauq, E.H. Koo and T.E. Golde: Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production. Nat Med. 11, 545-550 (2005)
143. F.G. De Felice, M.N. Vieira, T.R. Bomfim, H. Decker, P.T. Velasco, M.P Lampert, K.L. Viola, W.Q. Zhao, S.T. Ferreira and W.L. Klein: Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc Natl Acad Sci U S A. 106, 1971-1976 (2009)
144. W.A. Pedersen, P.J. McMillan, J.J. Kulstad, J.B. Leverenz, S. Craft and G.R. Haynatzki: Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Exp Neurol. 199, 265-273 (2006)
145. L. Escribano, A.M. Simón, A. Pérez-Mediavilla, P. Salazar-Colocho, J. Del Río and D. Frechilla: Rosiglitazone reverses memory decline and hippocampal glucocorticoid receptor down-regulation in an Alzheimer's disease mouse model. Biochem Biophys Res Commun. 379, 406-410 (2009)
146. G.S. Watson, B.A. Cholerton, M.A. Reger, L.D. Baker, S.R. Plymate, S. Asthana, M.A. Fishel, J.J. Kulstad, P.S. Green, D.G. Cook, Kahn S.E. M.L. Keeling and S. Craft: Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry. 13, 950-958 (2005)
147. G. Landreth, Q. Jiang, S. Mandrekar and M. Heneka: PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease. Neurotherapeutics. 5, 481-489 (2008)
148. C. Qiu, W. Xu and L. Fratiglioni: Vascular and psychosocial factors in Alzheimer's disease: epidemiological evidence toward intervention. J Alzheimers Dis. 20, 689-697 (2010)
149. S. Ray, M. Britschgi, C. Herbert, Y. Takeda-Uchimura, A. Boxer, K. Blennow, L.F. Friedman, D.R. Galasko, M. Jutel, A. Karydas, J.A. Kaye, J. Leszek, B.L. Miller, L. Minthon, J.F. Quinn, G.D. Rabinovici, W.H. Robinson, M.N. Sabbagh, Y.T. So, D.L. Sparks, M. Tabaton, J. Tinklenberg, J.A. Yesavage, R. Tibshirani and T. Wyss-Coray: Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med. 13, 1359-1362 (2007)
150. A. Pani, S. Dessí, G. Diaz, P. La Colla, C. Abete, C. Mulas, F. Angius, M.D. Cannas, C.D. Orru, P.L. Cocco, A. Mandas, P. Putzu, A. Laurenzana, C. Cellai, A.M. Costanza, A. Bavazzano, A. Mocali and F. Paoletti: Altered cholesterol ester cycle in skin fibroblasts from patients with Alzheimer's disease. J Alzheimers Dis. 18, 829-841 (2009)
151. C.H. Saely, P. Rein and H. Drexel: Combination lipid therapy in type 2 diabetes. N Engl J Med. 363, 692 (2010)